Abstract Objective The aim of this study was to evaluate the predictive factors of central lymph node metastasis (CLNM) and BRAF V600E mutation in Chinese patients with papillary thyroid carcinoma (PTC). Methods A total of 943 PTC patients who underwent thyroidectomy from 2014 to 2016 at our hospital were enrolled. Those patients were divided into PTC > 10 mm and papillary thyroid microcarcinoma (PTMC) groups by tumor size. The BRAF V600E mutation was examined by quantitative real-time PCR. Univariate and multivariate analyses were used to examine risk factors associated with CLNM and the BRAF V600E mutation. Results The frequency of CLNM was 53% (505/943). Both univariate and multivariate analyses suggested that the risk factors for CLNM i...
Background: The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid ca...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
SummaryObjectivesBRAF pV600E mutation is the most common oncogenic event and the most specific mutat...
To evaluate the molecular diagnosis marker of papillary thyroid carcinoma (PTC), the relationship be...
Background. Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC) worldwi...
Summary: Background: Presence of lymph node metastases increases the risk of recurrence, but prophy...
Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. ...
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an ep...
BRAF V600E is a possible biomarker for risk stratification and prognostication in papillary thyroid ...
Abstract Background While some studies suggest that the BRAF V600E mutation correlates with a high-r...
Objective. The aim of this study was to identify the risk factors associated with central lymph node...
Wen-Xu Jin,1,2,* Dan-Rong Ye,2,* Yi-Han Sun,2,* Xiao-Fen Zhou,2 Ou-Chen Wang,2 Xiao-Hua Zhang,2 Ye-F...
Haoyu Ren,1 Yifan Shen,2 Daixing Hu,1 Wei He,1 Jing Zhou,1 Yijia Cao,1 Yu Mao,1 Yi Dou,1 Wei Xiong,1...
<div><p>Introduction</p><p>The risk of over-treatment in low-advanced PTC stages has prompted clinic...
Abstract Background Papillary thyroid carcinoma (PTC) is one of the most frequent endocrine malignan...
Background: The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid ca...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
SummaryObjectivesBRAF pV600E mutation is the most common oncogenic event and the most specific mutat...
To evaluate the molecular diagnosis marker of papillary thyroid carcinoma (PTC), the relationship be...
Background. Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC) worldwi...
Summary: Background: Presence of lymph node metastases increases the risk of recurrence, but prophy...
Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. ...
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an ep...
BRAF V600E is a possible biomarker for risk stratification and prognostication in papillary thyroid ...
Abstract Background While some studies suggest that the BRAF V600E mutation correlates with a high-r...
Objective. The aim of this study was to identify the risk factors associated with central lymph node...
Wen-Xu Jin,1,2,* Dan-Rong Ye,2,* Yi-Han Sun,2,* Xiao-Fen Zhou,2 Ou-Chen Wang,2 Xiao-Hua Zhang,2 Ye-F...
Haoyu Ren,1 Yifan Shen,2 Daixing Hu,1 Wei He,1 Jing Zhou,1 Yijia Cao,1 Yu Mao,1 Yi Dou,1 Wei Xiong,1...
<div><p>Introduction</p><p>The risk of over-treatment in low-advanced PTC stages has prompted clinic...
Abstract Background Papillary thyroid carcinoma (PTC) is one of the most frequent endocrine malignan...
Background: The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid ca...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
SummaryObjectivesBRAF pV600E mutation is the most common oncogenic event and the most specific mutat...